by Fergus R Ferguson MD FRCP (Manchester) For this Address I have chosen a clinical subject, myasthenia gravis, because, as far as I know, I had not seen and certainly had not recognized a case before going to the National Hospital, Queen Square, in 1927 -although I had been seeing patients for ten years previouslyand because I think it has been rather a neglected subject in medical neurology. Certainly it is a condition which we now recognize much more frequently than ten years agoin fact, last year at the Royal Infirmary, Manchester, we saw 18 new patients with myasthenia gravis and a similar number (19) with motor neuron disease.
So we must ask ourselves if it is as rare as many think and say. Why do some of my senior colleagues say they would prefer to see almost any neurological condition rather than myasthenia gravis? Is the prognosis in the majority as bad as many think? It has been said before, and I think it is true, that the condition is not recognized as early as it should be. Has thymectomy, which has occupied so much time of so many for two decades, blurred the picture and interfered with the full and correct management by medical measures?
In a discussion of myasthenia and its management tribute must be paid to the workers in the United States of America - Grob, Viets, Schwab, Osserman, Eaton and Clagett - and in this country to Keynes, Garland, Ross and Simpson. Material My opinions are based on experience of 145 patients seen during the past twenty-eight years; all were examined and followed up in the Department of Neurology in the University of Manchester and the Manchester Royal Infirmary. The numbers may not be as large as in some other series recorded, but the series is characterized by the long duration of the follow up, its personal nature and the frequent detailed examinations.
Although in the past thirty-four years I have seen many other patients with myasthenia gravis, this personal group is the only one used for prognosis and assessment of functional status.
All the traced survivors were reviewed and reexamined three times in the last nine yearsin 1952, 1954 and 1961 . On each occasion there was a team of three observers, so that a joint opinion on the diagnosis and functional status of each patient was obtained. No case arousing doubt in the mind of any observer about the diagnosis has been included in the series. The overall picture of the results is indicated in Table 1 . Dead 37 (7 operated) Surviving and examined 96 (5 operated) Follow-up period: Maximum 28 years, minimum 2 years Of the untraced patients 2 had emigrated. Both were young men and their relatives report that they are quite well and are performing full work; they are not included in the assessment as I have not recently examined them personally.
The sex distribution of the patients shows a 2: 1 tendency in favour of femalesas reported in this and other seriesfor there are 94 females and 51 males. The age distribution curve shows that the maximal incidence is in the second, third, fourth and fifth decades. In other words, in general this series conforms to other published reports.
Survival Periods and Causes ofDeath
Of the 133 patients who have been traced, 30 who were treated medically are known to have died. Fifteen of these died of myasthenia gravis; of the others 8 died of carcinoma, the sites being gastrointestinal tract 5, breast 1, bladder 1, and bronchus 1. In the remaining 7 the causes of death were coronary occlusion 3, lung abscess 1, left ventricular failure 1, acute pancreatitis 1, and cause undetermined 1.
Of the 12 patients who underwent thymectomy, 7 have died and in each case from myasthenia. It is difficult to conceive of the ideal method of reporting the assessment of the clinical status of a given patient. Attempts have been made in the past to correlate degrees of improvement or deterioration with the number of tablets of neostigmine taken each day. In many ways this is unsatisfactory and it is my view that the best criterion of the state of the patient must take into account his practical working capacity, assuming that he is taking the optimum dosage of neostigmine. The classification I favour is the one proposed in 1955 (Ferguson et al. 1955 ) and relates to working status independent of neostigmine dosage. The grading is seen in Fig. 1 .
I wish to stress the fact that 70% of these patients who have been observed over periods ranging from two to twenty-eight years are at full work. From a practical economic point of view, therefore, myasthenia gravis in the majority of patients does not interfere with the usefulness of the patient to the community. This fact is emphasized by a reference to one patient, a woman now aged 46, who started with symptoms of myasthenia gravis twenty-five years ago. The true diagnosis was made only six years ago, and although she has generalized symptoms she is still working as a conductress on a double-decker bus which covers a route some 70 miles long. Last month she worked in successive weeks ninetytwo, seventy-two and eighty-seven hours.
Pregnancy and Myasthenia Gravis
The association of myasthenia gravis with pregnancy is infrequent, but when it does occur the problem is important and the available information is meagre and variable.
Earlier in this century medical opinion appeared to be agreed that pregnancy had an ad-verse effect upon myasthenia gravis. This view was countered by the experience of Laurent (1931) whose patient had 7 pregnancies, including 4 miscarriages and 1 therapeutic abortion. The course of the myasthenia during pregnancy was variable but in the main tended to be worse. In 1931, however, twenty-nine years after the onset of the condition, the patient appeared to have only minimal myasthenic affection. Viets et al. (1942) concluded that the effect of pregnancy on myasthenia gravis was usually favourable but that relapses mainly occurred in the first trimester. Fraser & Turner (1953) reported their observations on 14 pregnancies and expressed the view that myasthenic patients could go through pregnancy without special difficulty, although there was some danger of relapse necessitating increased doses of neostigmine during the first three months. They felt that there was no special medical indication for termination and added that in their opinion the greatest danger of relapse was during the first three weeks of the postpartum period and that such relapses occurred in about half their patients. Table 2 shows the general picture of myasthenia and pregnancy in my series; 14 deteriorated during pregnancy and 12 improved. Fifteen changed in the first three months and 9 in the second three months.
These figures emphasize the general unpredictability of the effect of pregnancy upon myasthenia. I conclude that: (1) Some myasthenics can go through pregnancy without any adverse change. Labour does not seem to present a problem.
(2) If a change is going to take place it is most frequent in the first three months and, to a lesser extent, in the second three months. This change may be equally for the better or for the worse.
(3) After only 7 of the pregnancies was there postpartum relapse in the first month, in contrast to the rather higher incidence in the patients of Fraser & Turner (1953) . Nevertheless, very careful supervision should be exercised during the postpartum period.
The following two case histories illustrate some of the special points of importance in the natural Section ofNeurology history and in the relationship of myasthenia to pregnancy.
Case 1 E N, now aged 51 She was first seen in 1955 and was then severely incapacitated. Her symptoms, ptosis and weakness of the arms and legs had developed at the age of 20, in 1930, but the condition was not diagnosed until twenty-five years after the onset.
In her first pregnancy, in 1933, she was very weak after three months and improved slowly in the postpartum period.
Two years later, in her second pregnancy, she had a severe relapse almost from the beginning. This pregnancy was terminated at three months and she improved slowly.
Three years later she had her third and last pregnancy. There was no relapse, no increase in her symptoms and delivery was normal.
Six years ago she showed an excellent response to medical treatment and now, thirty-one years after the onset of her myasthenia, there are no signs, apart from very slight ptosis, and she is perfectly well and doing normal housework.
Case 2 E R, now aged 40
Eleven years ago (1950) she developed ptosis and dysphagia. In 1951, within two months of conception, she had a severe generalized relapse. She was extremely ill with marked difficulty in respiration and expectoration and severe weakness of the laryngeal, pharyngeal and limb musculature. As a result pregnancy was terminated and she reverted to her normal level within forty-eight hours. Now, ten years later, she lives a full and active life.
Thus, although the condition is very variable in pregnancy and it is impossible to predict what is going to happen in a particular patient, we have now experience with these 34 pregnancies on which to base advice in the future.
Ocular Myasthenia
This aspect of myasthenia stirred me strongly some nine years ago when a patient with minor ocular symptoms (whom I had known well) moved to the south with her husband and within six months she had had her thymus removed and had died. I do not regret intensifying my inquiry since then.
Like Grob (1953) , I drew attention, in 1955, to the importance of assessing such cases separately in any consideration of the results of medical or surgical management. Grob had followed 48 patients of this type for an average period of eight and a half years without encountering a single death. In 1955 my survey showed that of 27 patients whose symptoms had remained confined to the ocular muscles, only 1 had died and he of carcinoma of the tongue at the age of 71. My experience of such patients has now risen to 50, and I have found that my original impression of the relative benignity of this condition has been confirmed, for there have now been only 8 deaths and none was due to myasthenia. The causes of death in these patients were: Coronary disease 2, carcinoma 4, lung abscess 1, and degenerative heart disease 1. The average age of these patients at death was 64+ years, which indicates that ocular myasthenia does not affect the expectation of life significantly. Tensilon test: No patient in whom a negative Tensilon test has been observed, however suggestive the previous history might have been clinically, has been included in this series. Over the past nine years, following the observations of Osserman & Kaplan (1952) , I have found the Tensilon test of great importance in confirming or refuting the diagnosis.
The prominence of ocular symptomatology in myasthenia gravis is well known and I have found that ocular symptoms occurred as the first manifestation of the disorder in 80 out of the 91 still living. Of these 80 cases 27 developed general manifestations within the space of three years and 9 more within periods ranging from three to twenty years. An analysis of the development of this extension from ocular to generalized symptomatology amongst our patients indicates that there is a general trend towards a better prognosis if this symptomatic transition takes place slowly. Further, if all the patients are reviewed (apart from those on whom there is inadequate information) it is found that out of 135, 100 began with ocular symptoms and about one-third (36) developed general manifestations within three years; in a further 12 patients general symptoms took more than three years to develop. On the other hand, in 50 patients the condition remained ocular. It seems then, that if there has been no spread from the ocular to generalized symptoms within three to five years there is a very good chance of the condition remaining ocular, with its excellent prognosis.
It has been suggested that pure ocular myasthenia is less frequent than has been reported and that detailed muscular examination may reveal unsuspected weakness or fatigability of other muscles. In the patient regarded as 'ocular' there may on testing be some paresis of the orbicularis oculi but no symptoms have been found referable to other muscle groups until the condition was diagnosed and recorded as becoming generalized.
In any event, I submit that the relatively excellent working status and the prognostic value provided in this review of the ocular myasthenics justify the clinical acceptance of the identity of this group.
It has also been suggested that patients with ocular myopathy have been included among the ocular myasthenics. On the contrary, this particu-lar group has been constantly borne in mind, and such instances have been eliminated by the negative results with the Tensilon test. Careful examination has revealed no difference in the type and nature of the ocular affection between those patients in whom the condition remains ocular and those in whom the condition later becomes generalized.
If, therefore, it is correct that there is a group justifying the term ocular myasthenia, then this is important. In this particular group there have been no deaths from myasthenia; the patients have little disability and adjust well to their symptoms by learning to turn the head and body or by wearing some special form of occluder. Further it is very likely that the condition may not become generalized if there has been no spread from the ocular to the general musculature within three to five years.
Special Features
It is often said that myasthenia invariably presents with ocular or bulbar manifestations. An analysis of the present series showed that in as many as 12 patients the presenting features did not include bulbar or ocular affection. In 5 of these the disorder presented as a general weakness, in 3 as a weakness of part or the whole of one or more limbs and in 4 patients as a weakness of the neck muscles.
Diagnostic stress is often laid upon the fact that the weakness is more prominent towards the end of the day. This is, of course, true with the majority but I do not think it is generally known that there is often another symptomatic peak in the early morning. As many as 24 of the patients reviewed in this group said that their disability was at its worst in the early morning, although 14 of them had a second symptomatic peak in the evening. The practical implication of this is that the early morning dose of neostigmine and a late night dose of pyridostigmine may be of great importance in the correct medical management. Enemata: Keynes (1949) drew attention to the possible danger of giving an enema to a myasthenic patient. We have records of 4 patients who developed severe or fatal symptoms after being given enemata. A study of these patients makes it clear that administration of enemata can produce widespread accentuation of myasthenic weakness and so it has been my practice to forbid the administration of an enema to any patient with myasthenia gravis at any stage of the disease. Thymectomy: Only 12 of the 145 patients in this series have undergone thymectomy and of these 7 had been operated on before I saw them.
Nevertheless, one must recognize the fact that thymectomy has had a period of twenty years in which to establish itself and yet its results are still quite unpredictable. The patients may be improved overnight, within a week, a month, in three months or twelve months, or on the other hand, may never show any improvement. When one considers the natural tendency of myasthenia to remit and to relapse, it is extremely difficult to assess the precise role of the thymus in the symptomatology of myasthenia and the potential value of thymectomy in its relief.
I am quite certain thymectomy is not justified in the ocular group. Moreover, one wonders on how many occasions thymectomy succeeded to the extent of abolishing the need for neostigmine in cases when correct medical management had previously failed to improve the condition.
On the other hand, I am certain that neostigmine is of great value in the majority of patients and here, I think, we must repair an omission. We have failed in Great Britain to pay adequate tribute to the pioneer work of Dr Mary Broadfoot Walker of 1934. In many ways Dr Walker's experience was extraordinary, for it appears, on looking back, that she had only some three months or so to establish evidence which led to our possession of neostigmine to-day. The essential facts were published in the Lancet of June 1934.
There were many remarkable features: (1) The patient had only two episodes of myasthenia over a period of thirty years, one at the age of 44 lasting six months, and one when she was 56 lasting about six months. (2) In the second episode when the symptoms had been very severe for three months, Dr Walker was able to carry out her physostigmine trials. (3) The patient happened to have no side-effects with the pharmacopceial physostigmine dose (gr 1/60), unlike all the other patients, where side-effects prevented further trials. (4) If the patient had experienced sideeffects with physostigmine and if Dr Walker had been more easily discouraged and not so quietly persistent, we might still have been looking for the medical treatment of mvasthenia gravis to-day.
